nach oben

Annals of Nuclear Medicine

Erschienen in:

30.01.2022 | COVID-19 | Letter to the Editor Zur Zeit gratis

Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy

verfasst von: Wajana Thaweerat

Erschienen in: Annals of Nuclear Medicine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Excerpt

Messenger RNA (mRNA) COVID-19 vaccine is one of the main vaccine types currently used for preventing SARS-CoV-2 infection worldwide. However, its administration can interfere with an FDG PET study since an increased uptake of 18F-FDG can be observed at the vaccine injection site and adjacent regional lymph nodes. The interpretation of PET study in oncologic patients might be impacted especially in head and neck cancer, breast cancer or lymphoma in which supraclavicular and axillary lymph node metastases are suspected. Hence, Advani et al. [ 1] suggest that FDG PET study should be performed at least 2 weeks after vaccination to reduce the interference of lymphadenopathy causing by vaccination in PET interpretation. …

Advani P, Chumsri S, Pai T, Li Z, Sharma A, Parent E. Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients. Ann Nucl Med. 2021;35(11):1264–9. https://doi.org/10.1007/s12149-021-01675-8. CrossRefPubMedPubMedCentral

Cohen D, Krauthammer SH, Wolf I, Even-Sapir E. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [18F]FDG PET-CT and relevance to study interpretation. Eur J Nucl Med Mol Imaging. 2021;48(6):1854–63. https://doi.org/10.1007/s00259-021-05314-2. CrossRefPubMedPubMedCentral

Eshet Y, Tau N, Alhoubani Y, Kanana N, Domachevsky L, Eifer M. Prevalence of increased FDG PET/CT axillary lymph node uptake beyond 6 weeks after mRNA COVID-19 vaccination. Radiology. 2021;300(3):E345–7. https://doi.org/10.1148/radiol.2021210886. CrossRefPubMed

Cohen D, Hazut Krauthammer S, Wolf I, Even-Sapir E. A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients. Eur J Nucl Med Mol Imaging. 2021;15:1–7. https://doi.org/10.1007/s00259-021-05579-7. CrossRef

Becker AS, Perez-Johnston R, Chikarmane SA, Chen MM, El Homsi M, Feigin KN, Gallagher KM, Hanna EY, Hicks M, Ilica AT, Mayer EL, Shinagare AB, Yeh R, Mayerhoefer ME, Hricak H, Vargas HA. Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: radiology scientific expert panel. Radiology. 2021;300(2):E323–7. https://doi.org/10.1148/radiol.2021210436. CrossRefPubMed

Titel: Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy
verfasst von: Wajana Thaweerat
Publikationsdatum: 30.01.2022
Verlag: Springer Singapore
Schlagwort: COVID-19
Erschienen in: Annals of Nuclear Medicine / Ausgabe 3/2022
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-021-01712-6

Corona-Update

Die aktuelle Entwicklung im Überblick: Nachrichten, Webinare, Übersichtsarbeiten.

» zum Update

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Optimization of FDG PET study after mRNA COVID-19 vaccination to reduce the interference of vaccine-associated hypermetabolic lymphadenopathy

Excerpt

Corona-Update

Hauptrubriken

Service

Fachgebiete

Themen

Sammlungen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging

Detection efficacy of PET/CT with 18F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study

Correction to: Serial change in perfusion–metabolism mismatch after coronary artery bypass grafting

Prognostic value of total tumour volume, adding necrosis to metabolic tumour volume, in advanced or metastatic non-small cell lung cancer treated with first-line pembrolizumab

Feasibility of 125I-RGD uptake as a marker of angiogenesis after myocardial infarction

I-124 PET/CT image-based dosimetry in patients with differentiated thyroid cancer treated with I-131: correlation of patient-specific lesional dosimetry to treatment response

Corona-Update